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HIV Infection Among Incarcerated Women
HIV infection among incarcerated women has become a hidden epidemic in the United States.
Factors that contribute to this epidemic include an increase of over 500% in the absolute number of
women incarcerated in 1999 compared to 1980, and a higher seroprevalence of HIV in incarcerated
women compared to US women in general (3.5% vs. 0.1%, See Figure 1).1 Together, these factors
have led to a steady increase in incarcerated women with HIV infection, compared to a plateau in
the number of HIV positive male offenders over the past five years. 
HIV infection has affected women of color disproportionately in the US as a whole, and the overrep-
resentation of women of color among incarcerated women magnifies the impact of HIV infection in
prisons. In the year 2000, in Texas (which ranks second only to California for the number of women
incarcerated), 22.8% of HIV positive incarcerated women were White, 72.4% were Black, and 4.8%
were Hispanic.2
The dramatic increase in the number of HIV infected women who are incarcerated means that more
and more correctional healthcare providers will be faced with the challenges of caring for these
women, and will need to know  the gender specific medical issues involved in providing care for
women with HIV. In addition, there are complex psychosocial issues such as depression, substance
abuse, and prior physical and sexual abuse that impact this population more frequently than their
HIV infected, non-incarcerated counterparts (See Spotlight).3, 4, 5 These co-morbidities may interfere
with their ability to cope with a stigmatized, chronic illness that requires adherence to a complex
medical regimen for successful treatment.   
HIV Testing in the Correctional Setting
Many of the issues regarding HIV testing for women have been addressed previously in this newslet-
ter (HEPP News April 2000, June 1999). However, given the high prevalence not only of HIV infec-
tion, but also high risk behaviors in incarcerated women, HIV risk education is perhaps the most
important part of HIV pre and post-test counseling.
Education regarding safer sexual practices and other risk reduction is an essential part of pre-test
counseling because this is when such counseling can have a real impact.  This information can (and
should) be repeated at post-test counseling, since
a women testing negative may erroneously con-
clude that her behaviors are not so risky after all.
Two other critical components of post-test educa-
tion should include discussion of the benefits of
early diagnosis and education regarding repeated
testing, especially if potential exposure continues.
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Figure 1. Factors contributing to increased risk of HIV among incarcerated women that
should trigger HIV screening, treatment and prevention education.
Numerous studies have shown that the same behaviors that lead to incarceration put women at increased
risk for HIV infection.23,24,25 Links between drug use, sex work, victimization, poverty, race and HIV explain the
prevalence of HIV infected women behind prison walls.
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The personnel providing pre and post-test
counseling must realize that for many
women, access and opportunity for health-
care outside the prison walls are limited by
multiple psychosocial  and logistical obsta-
cles. Incarceration is a unique opportunity
for education and empowerment of these
women regarding health promotion, dis-
ease prevention, and disease process.
However, incarceration does create real
concerns about loss of confidentiality and
fear of stigma that can prevent women from
presenting for voluntary testing while in
custody.   HIV testing and education should
be offered more than once during incarcer-
ation, especially to women with the follow-
ing conditions: pregnancy, diagnosis of
prior or current sexually transmitted dis-
ease, diagnosis of cervical neoplasm or
dysplasia, diagnosis of Hepatitis B or C,
history of commercial sex work, history of
sexual abuse, or history of drug use.  
Treatment of HIV-
Infected Women
The initial medical evaluation of an HIV
infected woman should include a thorough
past medical history, social history, and
review of systems as outlined in Table I.
Given the high rate of STDs and cervical
neoplasia in HIV infected women, physical
examination beyond the standard exam
should include pelvic exam with Pap smear
and STD screening (See HIV 101 page 7
and HEPP News, April 2000). Laboratory
evaluation should include screening for
other blood borne infections (Hepatitis B
and C), TB exposure (PPD), and baseline
hematology and chemistries, including liver
panel (both for baseline prior to beginning
therapy, and to screen for other co-morbid
conditions), as well as CD4 counts and HIV
viral load.  
By far, the most important part of the initial
encounter with an HIV positive woman is
identifying potential obstacles to adherence
with treatment and return to clinic. Before
choosing a specific regimen, clinicians
should assess the patients knowledge
about HIV infection and treatment options,
and discuss therapeutic agents, possible
side effects, timing of medications, and the
importance of adherence once therapy is
initiated. A critical component of continuing
care is linking the patient with care
providers to access once she is released.
Current Recommendations
for Initiating
Antiretroviral Therapy
In February 2001, the Panel on Clinical
Practices for Treatment of HIV Infection
convened by the Department of Health and
Human Services (HHS) revised its guide-
lines for the use of antiretroviral agents in
adults (see HEPP News, February 2001).6
The most recent change in the HHS guide-
lines are the recommendations regarding
initiation of therapy in the asymptomatic
HIV-infected patient, which were summa-
rized in the February 2001 issue of HEPP
News. (It must be noted that these recom-
mendations apply only to chronically infect-
ed patient, not to patients with acute HIV
infection).  The recommendation to wait for
a CD4 count of <350 or a viral load of
>50,000 by PCR i.e., more advanced
infection is in reaction to the greater
appreciation of the adverse metabolic
effects of long term antiretroviral therapy.
Adverse effects can be seen with all the
classes of agents currently available, and
for most people with HIV infection, therapy
will be continued lifelong. Thus, the new
HHS guidelines recommend delaying initia-
tion of therapy until the risk of disease pro-
gression justifies the risk of antiretroviral
therapy. However, there is reason to
believe these guidelines will be modified
again this year due to new information on
gender differences in viral loads.
Initiating Antiretroviral
Therapy in Women
The HHS guidelines rely heavily on HIV-1
viral load as a predictor of disease progres-
sion; and much of the data linking viral load
to development of AIDS comes from longi-
tudinal studies of male populations, such
as the MACS cohort.7, 8 However, multiple
studies have shown that women at all
stages of HIV infection have lower mean
HIV-1 viral loads than men, even after con-
trolling for CD4 count.9, 10 Researchers  at
Johns Hopkins University (JHU) and the
National Institute of Allergy and Infections
Disease (NIAID) recently published results
in the New England Journal of Medicine
from one of the largest studies ever to
examine gender-specific difference in HIV
infection, the AIDS Linked to the
Intravenous Experience or ALIVE cohort.
The study found that women who devel-
oped AIDS had a median initial viral load of
17,149 copies/mL, compared to 77,822
copies/mL in men. This sex difference in
viral load means that the same viral load
measurement does not convey the same
risk of AIDS in women and men. Under cur-
rent treatment guidelines, which suggest
initiation of antiretroviral therapy when viral
load exceeds 50,000, many women in the
ALIVE cohort would have been excluded
from HIV therapy. The results of the NIAID
and JHU study suggest that decisions con-
cerning the initiation of HIV therapy should
emphasize CD4+ count more than viral
load.11
A possible mechanism for this gender-
based discrepancy is a difference in the
expression of the HIV virion target on T-
cells (CCR5 co-receptor) in women versus
men. Portales and others have demonstrat-
ed a lower membrane density of CCR5 in
women, which they postulate may be
caused by the inhibitory effects of proges-
terone on CCR5 expression.12 Because the
membrane density of CCR5 determines the
in vitro infectability of a target cell by an
HIV-1 R5 strain, this finding could account
for the gender difference seen in HIV-1 viral
loads. Thus, clinicians caring for the HIV
infected woman should probably empha-
size CD4 T cell count over viral load when
making decisions about initiating HIV treat-
ment.
Pregnancy
Pregnancy presents another set of consid-
erations for HIV treatment, where there is
the additional goal of preventing vertical
transmission. Given the decrease in verti-
cal transmission seen with a zidovudine
(AZT, Retrovir) alone regimen in PACTG
076, it is generally agreed that zidovudine
should be part of any antiretroviral regimen
prescribed during pregnancy unless
absolutely contraindicated.13 The 2001
HHS Treatment Guidelines recommend
treatment with combination HAART (updat-
ed treatment guidelines, specific to preg-
nancy, are available at http://hopkins-
aids.edu/publications/report/may01_1). 
It is less clear how to manage the HIV
infected pregnant woman who has a high
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Table 1. Pertinent Elements of History in Initial Encounter of HIV Infected Women
Past Medical
History
Past
Medication Use
and Allergies
Social History
Review of
Systems
Identify Comorbid Conditions that may complicate care of HIV 
infection (i.e., Hepatitis B or C, Diabetes, Post-Traumatic Stress
Disorder, depression, low self-esteem, or anxiety disorders, etc)  
Initial screen for prior antiretroviral exposure and possible toxicities or
resistance; possible drug interactions with antiretrovirals or other 
indicated medications; specifically identify alternative medicine use
(pt may not volunteer this information).
Identify high-risk behaviors, so pt can be counseled re: prevention of
infection with more virulent or resistant strain of HIV. Identify potential
obstacles to medical therapy such as illiteracy, substance
abuse/addiction, sexual abuse, partner uses injection drugs or is HIV-
infected and psychiatric illness.
Should include specific questions regarding menstrual history, 
symptoms of gynecologic infection or malignancy, symptoms of
depression or anxiety, as well as screening for symptoms of 
underlying opportunistic illness.
Dear Colleagues,
I’ve worked with incarcerated HIV-infected women for 12 years - as long as my son is old. He was
just a newborn when I started this work, and he has lived in it, and around it, ever since. Likewise,
my daughter traveled with me to prison (in my belly), and so her being is woven into all of my
memories about caring for women in prison. Greater than 80% of my patients are also mothers
of young children. Their talk about their children opens their lives to me and creates that critical
bond of trust between patient and physician. Most of these women had primary custody of their
children before their incarceration. Who cares for their children when they cannot?
I cannot help but think about my patients’ children as I walk through the three steel doors at the
prison gate to get to my clinic. I walk through the same doors to leave. Going in, coming out, there
is always another child at the gates. I ask: what are we doing? Is anyone thinking about the next
generation? What will happen to these children? I certainly don’t know any easy solutions, but I
can’t believe that separating a child from a mother who has HIV, or AIDS, is the right thing to do.
HEPP’s tradition has been to publish an article about HIV infection in women around the time of
Mothers’ Day, in honor of the mothers who work in prisons and jails, in the hope of helping women
living with HIV in prisons and jails, and in remembrance of the children of incarcerated mothers.
This year, Dr. Onorato of U. Texas Medical Branch summarizes new information on the manage-
ment of HIV-infected women in corrections, including the impact of gender-related differences in
viral load. Betsy Stubblefield summarizes the recent NIJ publication on women and the justice
system, highlighting new data on violence against women.
Some good news wed like to report comes from one of our Advisory Board members: Dr. Lester
Wright, Medical Director of the New York State Department of Correctional Services. Although the
HIV infection rate among women in the NYDOC had been quite steady at 18 - 20% for 10 years,
the 2000-01 DOH study, still in analysis, appears to show a change.  Based on preliminary and
incomplete data the rate is in the 14% range. Thus we may be seeing a break in the "steady
increase in incarcerated women with HIV infection."  That is great news!
After reviewing this issue, readers should be able to describe the management of HIV infection
among women and special management issues related to pregnancy, discuss the appropriate
management of cervical cytology for women who are HIV infected, and understand the implica-
tions of gender and viral load in progression to AIDS.
Sincerely,
Anne S. De Groot, M.D.
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4CD4 count and low HIV-1 viral load.  There is
no data to suggest that combination therapy
would be better than zidovudine monothera-
py in preventing vertical transmission, but
combination therapy does have the advan-
tage of better virologic suppression for the
mother and less chance of developing resis-
tance mutations that might limit options for
treatment in the future. The pros and cons of
limiting fetal exposure to multiple agents ver-
sus preserving options for the mother in the
future should be discussed in detail with the
patient. The physician and patient should
also discuss the potential benefit of ceasari-
an section.
If treatment is to be initiated for the first time
during pregnancy, initiation of antiretroviral
therapy should wait until the second
trimester to minimize teratogenicity and
avoid gastrointestinal toxicity during the early
stage of pregnancy. Clinicians should avoid
using efavirenz (Sustiva) in pregnancy
because of evidence of teratogenicity in pri-
mate studies. The combination of didanosine
(DDI, Videx) and stavudine (D4T, Zerit)
should also be avoided because of multiple
case reports of hepatic steatosis with lactic
acidosis in pregnant women, including three
deaths.   
Other GYN Considerations
HIV-infected incarcerated women have par-
ticularly high rates of cervical cytological
abnormalities, sexually transmitted diseases
and certain gynecologic infections.14,15
Research indicates that vaginal infections
are slightly more common among HIV-infect-
ed incarcerated women than noninfected
incarcerated women, while the prevalence
rates of STDs are high among incarcerated
women compared to free-living women over-
all.16
Furthermore, high rates of HPV infection, of
cervical cytological abnormalities and of
invasive cervical cancer, have been found
among high-risk HIV-seronegative women
and HIV-infected incarcerated women.17
Most correctional HIV programs have adopt-
ed an increased level of vigilance for cervical
cancer, leading to the institution of perform-
ing pap smears every six months as a rou-
tine component of care for HIV-infected
women (See HIV 101, page 7). 
G Human Papilloma Virus (HPV) and
Cervical Cancer
A womans lifetime risk of HPV infection is
80%. Certain types of HPV are associated
with increased risk for cervical cancer. As a
consequence of cervical cytology screening
programs, cervical cancer is typically diag-
nosed in early stages. While patients with
stage I disease can be treated effectively
with either surgery or radiation therapy,
patients with stages II-IVa disease usually
receive radiation therapy as the primary
treatment modality. Forty percent of patients
develop persistent, recurrent or widely
metastatic disease for which there is current-
ly no consistently effective therapy. (See HIV
101) for treatment recommendations.
G Abnormal Menstruation
Although the Womens Interagency HIV
Study data suggests a similar rate of men-
strual irregularities in HIV-infected and unin-
fected women, there is data to suggest that
prolonged anomenorrhea is more common in
HIV-infected women.
Selected Antiretroviral
Toxicities and Monitoring
Lactic Acidosis and Hepatic Steatosis
Women are at higher risk for severe lactic
acidosis and hepatomegaly with steatosis.
Although  rare, these conditions are serious
and potentially fatal complications of nucleo-
side analogue reverse transcriptase inhibitor
(NRTI) therapy.18 Risk factors for this syn-
drome include gender (female), obesity, and
prolonged NRTI therapy.19 Clinical symptoms
are non-specific, but can include nausea,
bloating, abdominal pain, anorexia, vomiting,
diarrhea, malaise, and weight loss. Because
of the difficulty in obtaining an accurate lac-
tate level, monitoring is mainly by clinical
symptoms and monitoring the electrolytes
(for acidosis) and liver chemistries every
three months or when symptoms consistent
with the syndrome are present.  
Fat Maldistribution
Fat maldistribution can be particularly prob-
lematic for HIV-infected women when it is
manifested as breast enlargement or central
obesity, contributing to musculoskeletal back
pain and negative body image. The actual
incidence of fat maldistribution in patients
receiving HAART is unknown as lack of a
standardized definition make diagnosis diffi-
cult, but estimates range from 6% to 80%.
Clinical finding include central obesity, breast
enlargement, cervicodorsal fat accumulation
(buffalo hump), peripheral fat wasting with
extremity wasting and vascular prominence,
and facial thinning.20,21,22 All of these morpho-
logic changes develop gradually, usually
after several months of therapy. 
Summary
Correctional facilities can expect to care for
an increasing number of HIV-infected
women. Healthcare providers have a unique
chance to educate and empower this popu-
lation, which is at increased risk for HIV
infection, and has high rates of HIV infection.
Providers will need to be aware of the gen-
der-specific issues in HIV care, such as
gynecologic complications of HIV infection,
management of the HIV positive pregnant
woman, and monitoring for the metabolic tox-
icities of antiretroviral therapy, which may be
more severe or more apparent in women.
New appreciation of these toxicities has led
to more conservative recommendations for
antiretroviral use, which should be interpret-
ed in light of the gender differences seen in
HIV-1 viral loads. Regular monitoring of mul-
tiple parameters can help pick up metabolic
toxicites of antiretroviral therapy before
patients are clinically symptomatic.
*Nothing to disclose.
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Spotlight: HIV in the Lives of Women as Criminals and Women as Victims
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A cycle of violence and crime exists in the lives of women who
are victims of domestic abuse.  A September 2000 report from
the 1999 National Institute of Justice (NIJ) Conference on
Criminal Justice Research and Evaluation states that women
who are most marginalized by society are vulnerable to both
[violence and illegal activity] (1). Vulnerability to violence and
illegal activity often leads to behaviors that put women at risk for
HIV infection. According to the Kaiser Family Foundation (KFF),
the proportion of women in new AIDS cases has been rising
rapidly over the past 15 years. In 1986, 7% of AIDS cases were
women, whereas the most recent data shows that proportion
has more than tripled: 23% of 1999 AIDS cases were women
(see Figure 1).(2). The 2000 NIJ report and the 2001 KFF report
provide the numbers that describe an increase in violence,
incarceration, and HIV infection among women in the United
States.
Violence against women is widespread
According to the NIJ, one million women are victims of violence
committed by an intimate each year. Some studies have found
the rate to be higher: the National Violence Against Women
(NAVW) survey found that 1.5 million women reported being
victimized, and 7-22% of all women have experienced domes-
tic assault. Another study found that one in three women report
physical attack within her lifetime.  Hospital data has revealed
that 37% of women who sought emergency hospital care in
1994 were victims of domestic abuse. 
Emotional abuse, as well as physical abuse, has a major impact
on the health of women. The NIJ report states that "Battered
women are four to five times more likely to require psychiatric
treatment and five times more likely to attempt suicide than non-
battered women." Many rape victims do not seek help from
state or private support systems due to fear, stigma, or other
emotional or physical obstacles. One study found that 84% of
rape victims did not report the rape to the police.(1) Inability to
access support systems, lack of trust in law enforcement agen-
cies, fear, stigma, and other emotional or physical obstacles
may explain why many women do not report to state or private
support systems.  These obstacles not only keep women from
getting help after a violent incident, they may put women at risk
for further exposure to violence.
Incarceration of women is increasing
faster than incarceration of men
Approximately 138,000 women are in prisons and jails in the
US, which is more than triple the 1985 women inmate popula-
tion (3). The prison population of women grew more than 10%
annually since 1990 in some states, compared to 6.4% for men
(See Figure 2). 
HIV/AIDS Among Women
Women constitute one quarter of Americans living with HIV
(200,000-225,000), and one fifth of Americans living with
advanced AIDS. While important treatment and prevention
advances have been made for HIV/AIDS, women do not appear
to have benefited at the same rate as men.  According to the
KFF report, new AIDS cases among men fell by 60% during the
1990s, while new AIDS cases fell only 36% for women (2).
Furthermore, HIV/AIDS has a higher impact on women of color.
The latest data shows that 49 per 100,000 AIDS cases in
women are African American, which is more than 21 times
greater than the rate among White women (2.3 per 100,000).
The case rate among Latinas is more than six times the rate for
White women (14.9 per 100,000).
People of color are also more likely to be incarcerated than
White people. According the Bureau of Justice Statistics, 16.2%
of Blacks and 9.4% of Hispanics are likely to be incarcerated at
some point in their lifetime, versus 2.3% of Whites (4).
Catch 22: Risking Incarceration and
HIV Infection
Incarcerated women typically have a history of unmet social,
education, health and economic needs, in addition to a history
of victimization. Thus it comes as no surprise that the primary
causes of incarceration among women are for nonviolent
offenses; violating laws that prohibit the sale and possession of
specific drugs. Drug sales and other nonviolent crimes are "sur-
vival crimes that women commit to earn money, feed a drug-
dependent habit, provide for their children, or escape terrifying
intimate relationships and brutal social conditions" (1). 
Women who have experienced violence are more likely to
engage in risk behaviors that can lead to incarceration as well
as HIV infection.  The NIJ reported on a study that found that
women who have been raped are 10 times more likely to use
illegal substances or alcohol. Furthermore, women who are
involved in illegal activity, who are in a precarious legal status,
or who are socially marginalized, may be less likely to call the
police or other agencies when they have experienced a violent
episode for fear that they might be caught.  Thus these women
are in a double-bind; for fear of being caught for a legal viola-
tion, they cannot report violent episodes.  By not reporting vio-
lent episodes, they put themselves at greater risk for further
abuse and even HIV infection. Proving this point, a 1996 survey
found that at least half of all female prisoners have experienced
some form of sexual abuse before their imprisonment.
Sex work is another major cause of arrest among women, and
also may be linked to a history of abuse.  According to the NIJ
by Elizabeth Stubblefield, Managing Editor HEPP News
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Figure1. Percentage of AIDS Cases that are Women
1986         1990          1995          1999
The proportion of AIDS cases that occur among women is steadily
increasing, and has more than tripled since 1986 (2). This table was
taken from the Kaiser Family Foundation Report on Women and
HIV/AIDS, May 2001.
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Figure2. Women and Men As Percentage of Jail Inmates (3).
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Continued on page 6
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Women
6HEPPigram: Management of Cervical Cytology
Cervical cytology performed Q 6 months*
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Unsatisfactory for
evaluation
Within normal 
limits
Benign cellular
changes
Epithelial cell
abnormalities
Repeat 
now
Infection or 
inflammation
1. Atypical 
squamous cells 
of undetermined
significance
(ASCUS).
2. Low grade
squamous 
intraepithelial
lesions (LGSIL).
3. High grade
squamous 
intraepithelial
lesions (HGSIL).
Treat according to
diagnosis
Repeat cytology in
3 months
Dysplasia No Dysplasia
Colposcopy with
directed biopsy
Repeat Q 6
months for all 
HIV-infected
patients and if
there is a history 
of anogenital 
HPV infection 
or SIL.
1. Gynecology consultation
2. Ablative therapy
Repeat cervical cytology in 6 months
Infection with human papillomavirus (HPV) has been causally linked with the development of
cervical cancer and over 90% of invasive cervical tumors harbor HPV DNA.1,2 Over 65 differ-
ent  HPV types have been indentified and grouped into low-risk or high-risk categories on the
basis of each types association with a benign or malignant disease process.3 The high-risk
types 16 and 18 can be detected in roughly 70% of all invasive cervical tumors. PCR technol-
ogy (polymerase chain reaction) has been the preferred methodology for virus identification
and typing on isolated DNA, and will become an adjuct means of diagnosing HPV.
Persistent HPV infection is more prevalent among HIV-infected women, thus clinicians should
be vigilant about Pap smears and close gynecologic follow-up. 
*Cervical cytology is recommended every 6 months because the correctional population of women is at
high risk for complications.
1. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., et al. Prevalence of human papil-
lomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer
(IBSCC) Study Group [see comments]. J.Natl.Cancer Inst., 87: 796-802, 1995.
2. Liaw, KL, Glass, AG, Manos, MM, Greer, CE, Scott, DR, Sherman, M, Bruk, et al.Detection of human
papilllomavirus DNA in cytologiacally normal women and subsetquent cervical squamous intraeptithelial
lesions. J Natl Cancer Inst. 91 (11) 954-60 1999.
3. Pecoraro, G., Morgan, D., and Defendi, V. Differential effects of human papillomavirus type 6, 16, and
18 DNAs on immortalization and transformation of human cervical epithelial cells.
Proc.Natl.Acad.Sci.U.S.A., 86: 563-567, 1989.
report, 90% of sexworkers have
been abused by a member of the
family, and 70% have been sexu-
ally abused between the ages of 3
and 14. One study found that of
130 prostitutes, 68% had been
repeatedly raped. NIJ report
author Judge Kay Senin states
that many of these women never
received the valuable life-skills
training that a healthful family
environment provides. These
girls see violence and sexual
exploitation as the norm. They
have never known responsible,
respectful, and caring adults and
peers; they have never learned
how to form durable relationships
based on mutual support and
affection."
Note:
The authors of the report recom-
mend more research be conduct-
ed, and suggest that current
research and intervention pro-
grams adjust to incorporate the
impact and prevalence of violence
in the lives of the women with
whom they work. 
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7Tx/how supplied
Podophyllin: 25%
crude extract in a
tincture of benzoin,
applied by 
physician
Podophyllotoxin
(Condylox): 0.5%
gel or solution
applied by patient
Cryotherapy with
liquid nitrogen
Alternative:
Trichloroacetic acid
(TCA): 35%-85%
solution
Imiquimod (Aldera)
Electrosurgery 
CO2  laser 
treatment
Wart
Warts on
moist
surfaces
Warts on
moist
surfaces
All cond-
tions
Genital
warts
Genital
warts
Cond-
yloma
External
genital
warts
Dose
Every week, paint on lesion, wash
off after 4-8 hours. Duration of 6
weeks
BID for 3 consecutive days each
week for 4-6 week treatment cycles.
One to two freeze-thaw cycles are
applied to each wart every 1 to 3
weeks.
Weekly or biweekly
Applied QD by patient on alternate
days 3 days a week.
Comments
G Local irritation, ulceration, scarring.  
G Phimoses and balanitis can occur if podophyllin is used
on the foreskin or glans penis.
G Systemic side effects may include, fever, nausea, vom-
iting, confusion, coma, ileus, renal failure, paresthesias,
polyneuritis and leukopenia.  Podophyllin is considered a
teratogen and should not be used during pregnancy.
G Complete response observed in 40% of patients after
six consecutively weekly treatments
Success rates approach 60% and side effects are less
than with the physician applied podophyllin preparations
Freezing can be painful and may result in blister or ulcer
formation. 80% of patients are free of warts during treat-
ment and 55% are clinically negative 3 months after treat-
ment is stopped.
TCA has the same or lower efficacy compared to cryother-
apy and results in more pain, ulceration, and is not readily
available.
A topical immunomodulator, has an efficacy similar to
cryotherapy and yields a low recurrence rate. It is more
effective than podophyllin in treating women with external
genital warts, (72% response rate) and equal or less effec-
tive in men, especially lesions on the penile shaft (33%
response rate). The response rate is slow, requiring at
least 10 weeks of therapy before a response is observed.
Local skin irritation occurs.
Wart clearance occurs in 95% of patients with at least 70%
of patients free of warts at 3 months. These methods are
recommended for lesions that are small in size and num-
ber and can be done under local anesthesia.  Scarring
may result.
60-90% response rate with recurrence rates between 5%
and 10%. The advantages are reduced bleeding and post-
operative pain. Disadvantages include the high cost of
laser surgery, increased healing time. This method should
be reserved for patients with more extensive lesions.
H
IV
 
1
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1 Treatment of Genital Warts by Lori Rodriques, M.D., Clinical Fellow, UCSF Dept. of Dermatology
The continuum of HPV infection ranges from clinical, to subclinical,
to latent disease. One percent of sexually active adults have clinical-
ly active disease. Five percent have subclinical lesions detected only
by enhancing techniques such as acetowhitening. Twenty-five per-
cent of sexually active adults have HPV DNA detected in areas with-
out clinical lesions or in areas that are acetowhite negative-this is
latent disease. While the risk of transmission among persons with
clinical active disease is not known, the majority of couples with vis-
ible genital warts have partners that are concordantly infected. The
risk of transmitting the infection from persons with subclinical or
latent infection is also unknown. Latent disease may be responsible
for the persistence of infection despite therapy.
Etiology
Numerous HPV types can cause genital warts. In general, HPV types
6 and 11 are low-risk types and produce benign lesions. High-risk
HPV types or those associated with anogenital cancer, most com-
monly in the transition zone of the cervix and anus, are usually
caused by HPV types 16 and 18. In a small group, HPV infection per-
sists and may progress to cancer. The exact mechanism for this is
unknown.
Clinically, condyloma appear as soft sessile masses, that average 2
to 5 mm in size but may reach several centimeters in diameter and
height.  Lesions are frequently multifocal and in general, their color is
gray, pale yellow or pink. In women, lesions appear on the vulva,
cervix, and perineum or about the anus.  In men, they can occur on
the penis or perianal area, and less frequently on the scrotum.
Patients are usually asymptomatic however, trauma to lesions can
cause bleeding, itching, or irritation.  In addition, women may experi-
ence vaginal discharge.  
Treatment of Genital Warts
Treatment is not shown to reduce the transmission to sexual partners
nor to prevent the progression to dysplasia or cancer. Because gen-
ital warts are sexually transmitted, investigation for other sexually
transmitted diseases is warranted. Women with genital warts or
those whose partners have genital warts should have a routine cer-
vical cytological screening (Papanicolaou smear) to detect cervical
dysplasia. See table above for specific information on treatment.
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Call for Abstracts  for a Special
Issue of AIDS Education &
Prevention. 
Abstract submission July 1, 2001 
The Evaluation and Program Support
Center, centered at the Rollins
School of Public Health of Emory
University and Abt Associates is
soliciting abstracts for a special issue
of the AIDS Education & Prevention 
An Interdisciplinary Journal. The
focus is "HIV and Corrections:
Innovative Approaches to Prevention,
Treatment and Care". 
For more information, contact:
jcoltha@sph.emory.edu
HIV/AIDS-Healthy Women, Healthy
World: 28th Annual Global Health
Council Conference
May 29-31, 2001
Washington, DC
Contact Global Health Council
20 Palmer Court
White River Jct, VT, 05001 
Call: 802.649.1340 
Fax: 802.649.1396
Email: conference@globalhealth.org 
The 5th Annual HIV Update:
Contemporary Issues in
Management
May 31-June 2, 2001
Cambridge, Massachusetts
Email: hms-cme@hms.harvard.edu
Visit: http://134.174.17.108/
conted-bin/hmscme
Call: 617.432.1525
Fax: 617.432.1562
Sponsors: Harvard Medical School,
Dept. of Continuing Ed.
CME credits are available.
Overview of Adult HIV Care for
Health Professionals
June 4-6, 2001 
Atlanta, Georgia
Email: pyeargi@emory.edu
Visit: http://www.seatec.emory.edu
Call: 404.727.2938
Fax: 404.727.4562
Sponsors: Southeast AIDS Training
and Education Center (SEATEC),
Emory University.
CME credits available.
"Management of the HIV/ Hepatitis
C Co-infected Patient"
A Live Videoconference Series
June 5, 2001  
12:30-3:30 p.m. EST
CME credits available through 
Albany Medical Center.
Call: 518-262-4674
Email: rosentjh@mail.amc.edu
Visit: www.amc.edu/patient/HIV/
hivconf.htm
Save the 
Dates
8
Resources & Websites
Two cases of Fatal and Severe Hepatitis
Associated With RIF and PZA
One of the recommended treatments for latent
tuberculosis infection (LTBI) is a 9-month regi-
men of isoniazid (INH). In some cases, an alter-
native is a 2-month regimen of rifampin (RIF)
and pyrazinamide (PZA). In September 2000, a
53 year-old incarcerated black man in New
York died of hepatitis after 5 weeks of RIF-PZA.
In December, 59 year-old white woman in
Georgia was admitted to a hospital because of
hepatitis after 7 weeks of this regimen. An April
MMWR report summarizes the findings of the
investigations of these incidents, which under-
score the need for clinical monitoring for
adverse effects in all patients receiving treat-
ment for LTBI. (MMWR, April 20, 2001/
50(15);289-291. Article available at
http://www.cdc.gov/mmwr/preview/mmwrhtml/
mm5015a3.htm).
Invasive Cervical Cancer Before 
and After HAART
An Italian study published in the April issue of
JAIDS sought to assess whether the incidence
of ICC has changed since the introduction of
HAART among women with a known duration
of HIV infection. Utilizing a prospective cohort
study, the Italian Seroconversion Study, the
authors researched the incidence of  Invasive
Cervical Cancer (ICC) before and after the
introduction of HAART in Italy. In the period
1981 to 1995, an increase was observed in the
incidence of ICC and other AIDS-defining dis-
eases. The trend continued only for ICC since
1996. According to the authors, it remains to be
seen whether the increase in ICC after HAART
is attributable to a decreasing competitive mor-
tality from other AIDS-defining diseases, or
whether, in fact, ICC "may not be greatly influ-
enced by severe immunosuppression, stress-
ing the importance of clarifying the role of
immunosuppression on the development of
ICC and thus of determining the direct effect of
HAART on ICC." (Dorrucci M, Suligoi B, Rezza
G et al. JAIDS. 4/1/01;  26: 377-380.) 
Tolerability and Antiviral 
Activity of Fortovase plus Ritonavir
Last month, Roche announced preliminary clin-
ical data from four ongoing studies comparing
the safety and efficacy of once-daily Fortovase
(1600 mg) in combination with 100 mg of riton-
avir, along with two nucleoside reverse tran-
scriptase inhibitors (NRTIs) vs. once-daily
efavirenz (600 mg) plus two NRTIs in treat-
ment-naïve HIV-positive patients. Fortovase
plus ritonavir was well tolerated in this trial.
Three patients discontinued participation in the
trial due to gastrointestinal disorders, pregnan-
cy or loss of contact. (International Workshop
on HIV Clinical Pharmacology in Noordwijk,
Netherlands, April 2-4, 2001). 
Correctional Facilities Respond 
Quickly to TB
About 250 youths and 200 staff members are
being tested for TB at Marion Juvenile
Correctional Facility in Ohio. Testing has been
ongoing since mid-April, when a doctor told a
staff member that she may have the disease.
Officials were diverting youths to other deten-
tion centers around the state and canceling
weekend visitations until test results were
released (Associated Press 5/2/01). In South
Carolina,  three inmates at the Broad River
Correctional Institution have early signs of TB,
and vulnerable inmates are no longer being
assigned to the prison, state health officials
said. No cases of TB have been confirmed, but
the inmates have been isolated while the tests
are analyzed. (Associated Press, 5/5/01)
News Flashes
Updated Guidelines for Managing HIV in Pregnancy From the USPHS Task Force: 
Available at: http://hopkins-aids.edu/publications/report/may01_1.html or call: 1-800-448-0440
Women and HIV/AIDS: Overlooked and Underserved 
A May 2001 Kaiser Family Foundation report to Capitol Hill examined the impact of HIV/AIDS
on women and discussed the challenges facing the health care providers who care for women
with HIV/AIDS. Materials from the briefing are available on the Kaiser Family Foundation web-
site at: http://www.kff.org/women .
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The AIDS Reader
http://www.medscape.com
AIDS Weekly Plus
http://www.aegis.com/pubs/aidswkly/default.asp
HIVLine
http://www.hivline.com
Hopkins HIV Report
http://www.hopkins-aids.edu/
Journal of AIDS/HIV
http://www.CCSPublishing.com/j_aids.htm\
NIH Department of AIDS Research
http://www.niaid.nih.gov/daids
Physicians’ Research Network (PRN)
Notebook
http://www.prn.org/ 
Project Inform: HIV Care and Information
http://www.projinf.org/
HIV/AIDS Treatment Information Service
http://www.hivatis.org
HIV Insite
http://hivinsite.ucsf.edu/
AEGiS: the largest HIV/AIDS resource on the
Internet
http://www.aegis.com
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through September 30, 2001. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.   An estimated ______ women are currently living with HIV in the
United States.
a)  20,000
b)  80,000
c)  138,000
d)  200,000
e)  2 million
2.  Indicate which of the following are false:
a) The proportion of inmates that are women has been 
increasing since 1985.
b) The proportion of AIDS cases that are women has been 
increasing since 1986.
c) New AIDS cases have fallen by 60% in the 1990s for both 
men and women.
d) None of the above is false.
e) All of the above are false.
3.  Which HPV types are considered high risk, or associated with
anogenital cancer?
a) Types I and II
b) Types 6 and 11
c) Types 16 and 18
d) All of the above
e) None of the above
4.  Current guidelines suggest initiating HAART when viral load
>50,000 and CD4<350. Recent studies have shown that women
may progress to AIDS at lower viral loads than men. How is it 
suggested clinicians should respond to this finding when making
decisions about women with HIV?
a) Clinicians should lower the viral load threshold for initiating 
HAART to account for the difference between women and men.
b) Clinicians should emphasize CD4 T cell count when deciding 
when to initiate HAART in women.
c) Clinicians should emphasize viral load when deciding when to 
initiate HAART in women.
5.  Which of the following antiretrovirals should be avoided in preg-
nancy?
a) Zidovudine
b) Nevirapine
c) Efavirenz
d) Didanosine with Stavudine
e) A and C
f) C and D
6.  Cervical Cytology should be performed every 6 months on
patients with which of the following conditions?
a) History of anogenital HPV infection
b) History of SIL
c) HIV infection
d) A and B
e) A and C
f) All of the above
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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